Ratings United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 16:29:13 18/06/2025 BST			5-day change	1st Jan Change
289.62 ^USD	+0.96%		+4.21%	-18.34%

06-17	United Therapeutics delivers 18th consecutive quarter of topline growth
06-16	United Therapeutics Insider Sold Shares Worth $3,079,514, According to a Recent SEC Filing	MT

Summary: United Therapeutics Corporation

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Highlights: United Therapeutics Corporation

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
With a P/E ratio at 10.38 for the current year and 10.09 for next year, earnings multiples are highly attractive compared with competitors.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses: United Therapeutics Corporation

The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.

Ratings Chart: United Therapeutics Corporation

Source: Surperformance

ESG chart: United Therapeutics Corporation

Source: MSCI

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Fundamentals (Composite)	Global Valuation (Composite)	Financial estimates revisions (Composite)	Capi.($)
	UNITED THERAPEUTICS CORPORATION				12.94B
	ELI LILLY AND COMPANY				710B
	JOHNSON & JOHNSON				367B
	NOVO NORDISK A/S				335B
	ABBVIE INC.				328B
	ROCHE HOLDING AG				258B
	NOVARTIS AG				230B
	ASTRAZENECA PLC				223B
	MERCK & CO., INC.				197B
	AMGEN INC.				156B
	Average				281.55B
	Weighted average by Cap.

See all sector ratings

Investor (Composite)

Trader (Composite)

ESG MSCI

BBB

Financials

Revenue growth

EPS growth

Capital Efficiency (Composite)

Net Margin

Financial Health (Composite)

Valuation

P/E

EV/Revenue

EV/EBITDA

PBR

Dividend Yield

Revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

Revenue revisions (1 month)

EPS revisions (1 year)

EPS revisions (4 months)

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (4 months)

Analysts' target price evolution (1 year)

Business Predictability

Surprise rates

Analysts' coverage

Analysts' recommendations divergence

Analysts' Target price divergence

Financial estimates divergence

ESG

Environment

Social

Governance

Controversy

Ethical controversies

Human rights controversies

Tax subsidies controversies

Sharia compliant

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes